Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.1
Journals
JPM
Special Issues
Complex and High-Risk Coronary Interventional Procedures
share announcement

Complex and High-Risk Coronary Interventional Procedures

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Clinical Medicine, Cell, and Organism Physiology".

Deadline for manuscript submissions: 10 February 2026 | Viewed by 1254

Special Issue Editors

Dr. Zoltan Ruzsa

E-Mail Website
Guest Editor
Department of Internal Medicine, Invasive Cardiology Division, University of Szeged, 6720 Szeged, Hungary
Interests: vascular medicine; cardiovascular system; stents; angiography; carotid arteries; coronary angioplasty; vascular diseases
Special Issues, Collections and Topics in MDPI journals
Dr. Toth-Gayor Gabor

E-Mail Website
Guest Editor
Department of Cardiology, Medical University of Graz, 8010 Graz, Austria
Interests: cardiovascular system; stents; angiography; coronary angioplasty; fractional flow reserve
Special Issues, Collections and Topics in MDPI journals
Dr. Alexandru Achim

E-Mail Website
Guest Editor
Department of Cardiology, “Niculae Stancioiu” Heart Institute, University of Medicine and Pharmacy, 400001 Cluj-Napoca, Romania
Interests: vascular medicine; cardiovascular system; stents; angiography; coronary angioplasty; vascular diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Background & history of this topic: Advanced percutaneous coronary intervention (PCI) techniques used during complex high-risk intervention (CHIP) include rotational, orbital, and laser, specialized antegrade and retrograde coronary artery chronic total occlusion (CTO) approaches, and complex bifurcation stenting. After receiving CHIP, patients often experience dramatic improvement in symptoms, improved quality of life, and less re-admissions to the hospital. We also include clinical subsets such as CHIP intervention in severe heart failure (HFrEF) and valve disease (aortic stenosis and mitral regurgitation).

Aim and scope of the special issue:

The goal of this Research Topic is the following:
1) To show long-term results of CHIP interventions such as CTO, bifurcation, multivessel, and left main PCI.
2) To highlight the importance of LVAD use in complex CHIP cases.
3) To update the current knowledge of technical aspect of complex CHIP PCI.
4) To gain exposure to CHIP-related complications and their management.

Cutting-edge research:

  1. Long-term results of CHIP (CTO, bifurcation) procedures.
  2. Short-term results of coronary CTO recanalization (CTO, bifurcation) interventions.
  3. CHIP procedures in ACS.
  4. New devices and approaches during CHIP procedures.
  5. New access sites to perform CHIP procedures.

The kind of papers that we are soliciting are as follows:

Potential topics include, but are not limited to, the following: left main intervention, bifurcation intervention, chronic total occlusion recanalization, and multivessel disease intervention.

Dr. Zoltan Ruzsa
Dr. Toth-Gayor Gabor
Dr. Alexandru Achim
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • complex high-risk intervention (CHIP)
  • coronary bifurcation
  • coronary chronic total occlusion
  • severe coronary calcification
  • protected PCI
  • access site I during CHIP procedures

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

9 pages, 762 KiB  
Protocol
The Design and Feasibility of Optimal Treatment for Coronary Drug-Eluting Stent In-Stent Restenosis (OPEN-ISR)—A Prospective, Randomised, Multicentre Clinical Trial
by Péter Márton Kulyassa, Balázs Tamás Németh, István Hizoh, Laura Krisztina Jankó, Zoltán Ruzsa, Zoltán Jambrik, Brúnó Bánk Balázs, Dávid Becker, Béla Merkely and István Ferenc Édes
J. Pers. Med. 2025, 15(2), 60; https://doi.org/10.3390/jpm15020060 - 2 Feb 2025
Viewed by 912
Abstract
Introduction: Percutaneous coronary intervention (PCI) with drug-eluting stents (DES) is a cornerstone of the management of ischemic heart disease. However, in-stent restenosis (ISR) remains a significant clinical challenge, occurring in approximately 5–10% of patients undergoing PCI. This study is designed to compare the [...] Read more.
Introduction: Percutaneous coronary intervention (PCI) with drug-eluting stents (DES) is a cornerstone of the management of ischemic heart disease. However, in-stent restenosis (ISR) remains a significant clinical challenge, occurring in approximately 5–10% of patients undergoing PCI. This study is designed to compare the efficacy and safety of the primary therapeutic approaches for DES-ISR, specifically drug-coated balloons (DCBs)—paclitaxel-coated balloons (PCBs) and sirolimus-coated balloons (SCBs)—with a new-generation everolimus-eluting stent (EES), contributing to the evolving field of personalized medicine. Methods and Analysis: This prospective, multicentre, randomised, non-inferiority trial aims to enroll 150 patients with DES-ISR, who will be randomised into one of the following: SCB, PCB, or EES. The primary endpoint comparing DCB and EES is late lumen loss (LLL) at 6 months, as measured by quantitative coronary angiography (QCA). Secondary endpoints comparing the three arms include a device-oriented composite endpoint, intraluminal gain, optical coherence tomography (OCT) measured LLL, and correlations between LLL and quantitative flow ratio (QFR). The primary endpoint will be analysed using a non-inferiority design, with a margin set at 0.25 mm, for which the sample size was calculated. Statistical analysis of the primary endpoint will be conducted on an intention-to-treat basis with a one-tailed Mann–Whitney U test with a significance level of 95. Secondary endpoints will be analysed via superiority testing using ANOVA, the Kruskal–Wallis test, logistic regression, or Fisher’s exact test, as appropriate. Ethics and Dissemination: The study protocol has been approved by the Medical Devices Department of the Hungarian National Institute of Pharmacy and Nutrition, ensuring compliance with ethical standards as outlined in the Declaration of Helsinki. All investigators declare no conflicts of interest related to this study. The trial is registered in ClinicalTrials.gov under the ID: NCT04862052. Full article
(This article belongs to the Special Issue Complex and High-Risk Coronary Interventional Procedures)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop